Lipicure CF 10 Capsule IR is a combination oral medication containing Atorvastatin 10 mg and Fenofibrate 135 mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Atorvastatin, a selective HMG-CoA reductase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C), total cholesterol, and triglycerides while modestly increasing high-density lipoprotein cholesterol (HDL-C). Fenofibrate, a fibric acid derivative, primarily lowers triglyceride levels and increases HDL-C by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles. The combined formulation targets multiple lipid abnormalities, providing a comprehensive approach to cardiovascular risk reduction in patients with persistent dyslipidemia despite lifestyle modifications. Lipicure CF 10 Capsule IR is particularly beneficial for patients with mixed dyslipidemia characterized by elevated LDL-C and triglycerides. The immediate-release (IR) formulation ensures prompt absorption and onset of action. Therapy should be initiated under medical supervision with periodic monitoring of lipid profiles, liver function tests, and renal parameters to detect potential adverse effects such as hepatotoxicity, myopathy, or rhabdomyolysis. This combination therapy should be used alongside diet, exercise, and other lifestyle interventions to optimize lipid control and reduce the risk of atherosclerotic cardiovascular disease.